Objective: Association studies on the effects of GGCX gene polymorphisms on warfarin stable dose have shown conflicting results. The aim of this study is to quantitatively summarize whether GGCX gene polymorphisms have potential roles in warfarin dose requirement. Methods: Publications were searched in PubMed, Medline and ISI Web of Knowledge and chosen by exact inclusion and exclusion criteria. A meta-analysis was conducted by using Revman 5.0 software to determine the association between common polymorphisms of the three genes and warfarin dose requirement. Results: Data were extracted from 13 publications with 4167 patients enrolled. Two common polymorphisms (rs699664, rs12714145) of GGCX were included for further meta-analyses. Comparing to rs699664AA geontype carriers, rs699664GG genotype carriers requered higer 3% [95% CI: 2% - 4%, P-valus < 0.0001] warfarin dose. The warfarin dosage requirement showed no significant difference between rs699664GG and rs699664GA genotype carriers, P=0.51. Compared to rs12714145AA carriers, the GG and GA genotype carriers needed 5% (95% CI, 1% - 9%; P = 0.01) and 4% (95% CI, 1% - 8%; P = 0.02) lower warfarin dosage, respectively. The warfarin dosage requirement showed no significant difference between GG and GA genotype carriers, P=0.12. Conclusion: Our study showed that GGCX polymorphisms were significantly associated with warfarin dose requirement. These polymorphisms should be considered in future warfarin personalized treatment.
| Published in |
American Journal of Life Sciences (Volume 3, Issue 1-4)
This article belongs to the Special Issue Pharmacogenomics & Personalized Medicine |
| DOI | 10.11648/j.ajls.s.2015030104.12 |
| Page(s) | 7-13 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2014. Published by Science Publishing Group |
GGCX, Warfarin, Polymorphism, Meta-Analysis
| [1] | Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007 2007-04-01;7(2):99-111. |
| [2] | The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990 1990-11-29;323(22):1505-11. |
| [3] | Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991 1991-08-01;18(2):349-55. |
| [4] | Burns M. Management of narrow therapeutic index drugs. J Thromb Thrombolysis. 1999 1999-04-01;7(2):137-43. |
| [5] | Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001 2001-01-01;119(1 Suppl):8S-21S. |
| [6] | Anderson JL, Horne BD, Stevens SM, et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007 2007-11-27;116(22):2563-70. |
| [7] | Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009 2009-02-19;360(8):753-64. |
| [8] | Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006 2006-02-01;16(2):101-10. |
| [9] | Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics. 2006 2006-02-01;16(2):101-10. |
| [10] | Moreau C, Loriot MA, Siguret V. [Vitamin K antagonists: from discovery to pharmacogenetics]. Ann Biol Clin (Paris). 2012 2012-10-01;70(5):539-51. |
| [11] | Stafford DW. The vitamin K cycle. J Thromb Haemost. 2005 2005-08-01;3(8):1873-8. |
| [12] | Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005 2005-01-20;5:13. |
| [13] | Lindh JD, Holm L, Andersson ML, Rane A. Influence of CYP2C9 genotype on warfarin dose requirements--a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009 2009-04-01;65(4):365-75. |
| [14] | Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR. Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One. 2012 2012-01-20;7(8):e44064. |
| [15] | Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement--a systematic review and meta analysis. Thromb Res. 2010 2010-04-01;125(4):e159-66. |
| [16] | Huang SW, Xiang DK, Huang L, et al. Influence of GGCX genotype on warfarin dose requirements in Chinese patients. Thromb Res. 2011 2011-02-01;127(2):131-4. |
| [17] | Cavallari LH, Perera M, Wadelius M, et al. Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics. 2012 2012-02-01;22(2):152-8. |
| [18] | Lee KE, Chang BC, Kim HO, et al. Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Ther Drug Monit. 2012 2012-06-01;34(3):275-82. |
| [19] | Choi JR, Kim JO, Kang DR, et al. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet. 2011 2011-04-01;56(4):290-5. |
| [20] | King CR, Deych E, Milligan P, et al. Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost. 2010 2010-10-01;104(4):750-4. |
| [21] | Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE. New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol. 2010 2010-09-01;70(3):393-9. |
| [22] | Ohno M, Yamamoto A, Ono A, et al. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients. Eur J Clin Pharmacol. 2009 2009-11-01;65(11):1097-103. |
| [23] | Kimura R, Miyashita K, Kokubo Y, et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res. 2007 2007-01-20;120(2):181-6. |
| [24] | Vecsler M, Loebstein R, Almog S, et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost. 2006 2006-02-01;95(2):205-11. |
| [25] | Loebstein R, Vecsler M, Kurnik D, et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther. 2005 2005-05-01;77(5):365-72. |
| [26] | Huang SW, Xiang DK, Wu HL, Chen BL, An BQ, Li GF. [Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2011 2011-12-01; 28(6):661-5. |
| [27] | Liang Y, Chen Z, Guo G, et al. Association of genetic polymorphisms with warfarin dose requirements in Chinese patients. Genet Test Mol Biomarkers. 2013 2013-12-01; 17(12): 932-6. |
| [28] | Zhong SL, Liu Y, Yu XY, et al. The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. Eur J Clin Pharmacol. 2011 2011-06-01; 67(6):581-90. |
| [29] | Brenner B, Sanchez-Vega B, Wu SM, Lanir N, Stafford DW, Solera J. A missense mutation in gamma-glutamyl carboxylase gene causes combined deficiency of all vitamin K-dependent blood coagulation factors. Blood. 1998 1998-12-15; 92(12): 4554-9. |
| [30] | Zhu A, Sun H, Raymond RJ, et al. Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase. Blood. 2007 2007-06-15; 109(12):5270-5. |
| [31] | Kinoshita H, Nakagawa K, Narusawa K, et al. A functional single nucleotide polymorphism in the vitamin-K-dependent gamma-glutamyl carboxylase gene (Arg325Gln) is associated with bone mineral density in elderly Japanese women. Bone. 2007 2007-02-01; 40(2):451-6. |
| [32] | Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005 2005-01-20; 5(4):262-70. |
| [33] | Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci. 2009 2009-07-01; 30(7): 375-86. |
APA Style
Zhiying Luo, Xi Li, Mouze Liu, Yan Shu, Jiye Yin, et al. (2014). Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis. American Journal of Life Sciences, 3(1-4), 7-13. https://doi.org/10.11648/j.ajls.s.2015030104.12
ACS Style
Zhiying Luo; Xi Li; Mouze Liu; Yan Shu; Jiye Yin, et al. Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis. Am. J. Life Sci. 2014, 3(1-4), 7-13. doi: 10.11648/j.ajls.s.2015030104.12
AMA Style
Zhiying Luo, Xi Li, Mouze Liu, Yan Shu, Jiye Yin, et al. Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis. Am J Life Sci. 2014;3(1-4):7-13. doi: 10.11648/j.ajls.s.2015030104.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajls.s.2015030104.12,
author = {Zhiying Luo and Xi Li and Mouze Liu and Yan Shu and Jiye Yin and Xiaoping Chen and Jianquan Luo and Xiaobing Li and Wei Zhang},
title = {Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis},
journal = {American Journal of Life Sciences},
volume = {3},
number = {1-4},
pages = {7-13},
doi = {10.11648/j.ajls.s.2015030104.12},
url = {https://doi.org/10.11648/j.ajls.s.2015030104.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajls.s.2015030104.12},
abstract = {Objective: Association studies on the effects of GGCX gene polymorphisms on warfarin stable dose have shown conflicting results. The aim of this study is to quantitatively summarize whether GGCX gene polymorphisms have potential roles in warfarin dose requirement. Methods: Publications were searched in PubMed, Medline and ISI Web of Knowledge and chosen by exact inclusion and exclusion criteria. A meta-analysis was conducted by using Revman 5.0 software to determine the association between common polymorphisms of the three genes and warfarin dose requirement. Results: Data were extracted from 13 publications with 4167 patients enrolled. Two common polymorphisms (rs699664, rs12714145) of GGCX were included for further meta-analyses. Comparing to rs699664AA geontype carriers, rs699664GG genotype carriers requered higer 3% [95% CI: 2% - 4%, P-valus < 0.0001] warfarin dose. The warfarin dosage requirement showed no significant difference between rs699664GG and rs699664GA genotype carriers, P=0.51. Compared to rs12714145AA carriers, the GG and GA genotype carriers needed 5% (95% CI, 1% - 9%; P = 0.01) and 4% (95% CI, 1% - 8%; P = 0.02) lower warfarin dosage, respectively. The warfarin dosage requirement showed no significant difference between GG and GA genotype carriers, P=0.12. Conclusion: Our study showed that GGCX polymorphisms were significantly associated with warfarin dose requirement. These polymorphisms should be considered in future warfarin personalized treatment.},
year = {2014}
}
TY - JOUR T1 - Moderate Effect of GGCX Polymorphisms on Patients Warfarin Dosage Requirement- A Meta-Analysis AU - Zhiying Luo AU - Xi Li AU - Mouze Liu AU - Yan Shu AU - Jiye Yin AU - Xiaoping Chen AU - Jianquan Luo AU - Xiaobing Li AU - Wei Zhang Y1 - 2014/12/27 PY - 2014 N1 - https://doi.org/10.11648/j.ajls.s.2015030104.12 DO - 10.11648/j.ajls.s.2015030104.12 T2 - American Journal of Life Sciences JF - American Journal of Life Sciences JO - American Journal of Life Sciences SP - 7 EP - 13 PB - Science Publishing Group SN - 2328-5737 UR - https://doi.org/10.11648/j.ajls.s.2015030104.12 AB - Objective: Association studies on the effects of GGCX gene polymorphisms on warfarin stable dose have shown conflicting results. The aim of this study is to quantitatively summarize whether GGCX gene polymorphisms have potential roles in warfarin dose requirement. Methods: Publications were searched in PubMed, Medline and ISI Web of Knowledge and chosen by exact inclusion and exclusion criteria. A meta-analysis was conducted by using Revman 5.0 software to determine the association between common polymorphisms of the three genes and warfarin dose requirement. Results: Data were extracted from 13 publications with 4167 patients enrolled. Two common polymorphisms (rs699664, rs12714145) of GGCX were included for further meta-analyses. Comparing to rs699664AA geontype carriers, rs699664GG genotype carriers requered higer 3% [95% CI: 2% - 4%, P-valus < 0.0001] warfarin dose. The warfarin dosage requirement showed no significant difference between rs699664GG and rs699664GA genotype carriers, P=0.51. Compared to rs12714145AA carriers, the GG and GA genotype carriers needed 5% (95% CI, 1% - 9%; P = 0.01) and 4% (95% CI, 1% - 8%; P = 0.02) lower warfarin dosage, respectively. The warfarin dosage requirement showed no significant difference between GG and GA genotype carriers, P=0.12. Conclusion: Our study showed that GGCX polymorphisms were significantly associated with warfarin dose requirement. These polymorphisms should be considered in future warfarin personalized treatment. VL - 3 IS - 1-4 ER -
Email: